TX-MARY-KAY-INC.
15.12.2022 17:06:38 CET | Business Wire | Press release
As a global leader in women’s empowerment and innovative science, Mary Kay Inc. announces six recipients of the 2022 Young Women in STEAM grant program for making tremendous contributions to STEAM fields worldwide – science, technology, engineering, the arts, and mathematics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221215005712/en/
Mary Kay Inc. provides grants to young women making great strides in STEAM-related fields around the world. (Graphic: Mary Kay Inc.)
In 2020, Mary Kay launched the Young Women in STEAM grant program and social campaign to help shift the perception of “the face of science,” and encourage young women to pursue STEAM paths. According to UNESCO, the United Nations Educational, Scientific and Cultural Organization, women remain a significant minority in scientific fields and are still under-represented in areas such as computing, digital information technology, engineering, mathematics, and physics.
“At Mary Kay, we celebrate young women who are embracing higher education and careers in STEAM areas as we continue to help narrow the gender gap and bias in scientific and related fields,” said Dr. Lucy Gildea, Chief Innovation Officer, Product and Science for Mary Kay Inc. “It’s no secret that women are underrepresented in STEAM industries, and we want to help change that by providing impactful grants to encourage young women to continue their pursuits in STEAM-related fields. Our 2022 Young Women in STEAM grant recipients are blazing trails around the world and helping to solve some of humanity’s most complex problems through science and innovation. We are proud to recognize their contributions and by supporting these remarkable young women, we continue Mary Kay’s steadfast mission of enriching women’s lives worldwide.”
The recipients of Mary Kay’s 2022 Young Women in STEAM grant program are highlighted on the company’s global social media channels and will receive $2,500 USD grants to assist with their current or future STEAM endeavors.
The 2022 Young Women in STEAM grant recipients:
- Angela Busheska, 20 (Macedonia) – The social entrepreneur and research-innovator was inspired to pursue STEAM after joining her 7th grade math Olympiad team where she fell in love with solving problems. As a developer of the EnRoute app, Busheska helps users live a more sustainable lifestyle by utilizing machine learning algorithms to help users abandon fast fashion. She encourages other young women to join STEAM fields and looks forward to seeing humanity utilize STEAM technologies for greater social good.
- Fengyun Chen, 17 (China) – Her projects entail physics and the role of clean energy in environmental sustainability. In 2017, Chen founded Yun Energy, an alliance of science and technology innovation that serves 20,000 people per year through courses in scientific enlightenment and physics. She conducted a 30-day investigation with her father that also led to the invention of the Water Distribution Device of Power Generated by Geothermal Energy and Air 3.0. She believes STEAM education allows students to explore practical ideas through hands-on experimentation that stimulates creativity and imagination.
- Farzana Alam Eshita, 23 (Australia) – As a civil engineer and honors student at the Monash University in Australia, Eshita’s final year project focuses on investigating the development of shear bands in triaxially loaded sand bands using x-ray computed tomography. Her current projects also include engineering major road projects in accordance with Australian standards and development of a landmark sports complex structure highlighting excellence in architectural and urban design. Eshita believes being a female in a STEAM field offers a variety of benefits including the opportunity to gain confidence, improve problem-solving abilities, and develop new educational and employment prospects.
- Aruna Sherma, 20 (Germany) – Her project is focused on developing an alternative contrasting agent for MRI scans that replace the conventional agent, gadolinium. As a physics student, Sherma has worked in four different labs to develop the contrast agent, and a series of tests at the University of Hamburg has shown it to be biocompatible with a stronger effect in MRI scans at a lower dosage than conventional contrast. Although STEAM subjects can be daunting to many, she believes diversity is important in all fields and feels women are just as capable as men of shaping the future in technology and research.
- Jingyuan Xu, 31 (Germany) – The energy conversion technologist and sustainable energy champion is a research fellow at the Karlsruhe Institute of Technology in Germany. Xu’s research focuses on sustainable energy technologies to provide economical solutions in cooling, heating, and power. She is passionate about applying her knowledge and expertise to minimize global-primary energy use and reduce CO2 emissions. In her view, women in STEAM boost team spirit, and the diversity that comes with inclusivity produces better science. She encourages young girls to pursue STEAM fields with enthusiasm and follow their hearts to benefit the world with breakthrough science.
- Eizelle Yee, 30 (Philippines) – An environmentalist, architect, and entrepreneur, Yee is a founding member of Pocket Garden, a public space design collective started by a group of volunteers who co-create and design shareable green spaces in the Philippines. She believes women have a keen eye for detail that helps marry art and science in an organized fashion. When it comes to STEAM initiatives, she feels collaborations between diverse cultures and traditions can bring inclusive and relatable creations in the fields of science, technology, engineering, the arts, and mathematics.
For more information on the Young Women in STEAM grant program, visit https://newsroom.marykay.com/.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005712/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
